Orchid Pharma

628.75
-6.80
(-1.07%)
Market Cap
3,189.00 Cr
EPS
19.06
PE Ratio
32.10
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
1,997.40
52 Week Low
635.55
PB Ratio
2.52
Debt to Equity
0.25
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from3 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %

Company News

View All News
Caret
positive
USFDA Issues EIR with VAI Status for Orchid Pharma2 days ago
Orchid Pharma has announced that the U.S. Food and Drug Administration (USFDA) has issued an Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status. This decision comes after the USFDA accepted the company's response to observations raised during a previous inspection.
neutral
Orchid Pharma: Q4 Revenue Up, EBITDA Margin Declines4 days ago
Orchid Pharma reported Q4 FY25 revenue of Rs 2,375 million, up 9.4% YoY and 9.3% QoQ. EBITDA was Rs 280 million, down 3.2% YoY but up 6.1% QoQ. EBITDA margin decreased to 11.8%, down 154 bps YoY and 35 bps QoQ.
positive
Orchid Pharma Reports Improved Q4 EBITDA and Margin5 days ago
Orchid Pharma has reported its latest quarterly results. The company's EBITDA for Q4 increased to 343.3 million rupees from 289.2 million rupees in the same quarter last year. The EBITDA margin also improved, rising to 14.46% from 13.32% year-over-year.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,677.60
#1 4,02,512.40
35.10
#1 49,887.20
12.06
#1 9,648
-18.99
42.28
6,612.00
1,75,527.80
80.12
8,184.00
0.89
1,600
23.05
63.47
1,465.70
1,18,372.10
22.44
26,520.70
14.17
4,155
30.28
44.20
3,174.70
1,07,446.30
55.71
10,785.70
11.59
1,656
10.91
44.55
1,251.20
1,04,407.10
#1 18.47
28,905.40
12.36
5,578
21.14
67.52
2,467.70
1,01,812.00
51.37
10,615.60
19.57
1,942
-10.91
48.86
930.00
93,579.80
20.04
19,831.50
13.82
3,831
-0.19
63.14
1,957.70
89,377.00
27.25
20,141.50
#1 19.94
1,936
#1 112.49
43.05
1,147.80
66,664.40
19.29
29,559.20
17.55
3,169
-0.50
43.00
30,455.00
64,714.70
45.75
6,097.20
10.80
1,201
27.83
50.48
Forecast
Actual
Growth Rate
Revenue Growth
24.06 %
Net Income Growth
72.28 %
Cash Flow Change
586.97 %
ROE
1.37 %
ROCE
-18.34 %
EBITDA Margin (Avg.)
10.70 %

Quarterly Financial Results

Quarterly Financials
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Revenue
141
138
137
93
120
110
105
131
95
196
164
180
134
171
169
251
185
207
228
231
252
230
226
241
Expenses
148
133
129
108
100
91
108
123
95
116
151
154
119
147
146
177
161
175
185
188
212
192
191
210
EBITDA
-7
6
7
-15
21
19
-3
8
0
79
13
26
15
24
23
74
24
32
43
42
40
38
35
32
Operating Profit %
-9 %
-1 %
0 %
-23 %
16 %
17 %
-5 %
-3 %
-3 %
9 %
7 %
13 %
10 %
11 %
9 %
16 %
12 %
12 %
16 %
13 %
13 %
14 %
12 %
12 %
Depreciation
31
32
32
23
30
30
29
20
20
20
20
27
22
18
8
7
8
8
9
8
8
9
9
9
Interest
0
0
3
1
14
13
13
12
11
10
7
5
8
9
8
8
6
4
4
4
4
3
4
4
Profit Before Tax
-39
-26
-28
-39
-23
-24
-45
-25
-31
49
-14
-6
-14
-3
7
59
11
20
30
30
28
26
23
19
Tax
0
0
0
0
0
0
0
0
0
0
0
1
1
2
-1
0
1
0
1
-3
-1
-1
2
-3
Net Profit
-39
-26
-28
-39
-23
-24
-45
-25
-31
49
-14
-7
-15
-5
8
59
9
20
29
33
29
27
21
22
EPS in ₹
-4.32
-2.93
-3.11
-9.52
-5.55
-5.98
-10.96
-6.06
-7.57
12.10
-3.40
-1.61
-3.68
-1.32
1.86
14.49
1.85
4.30
6.18
6.81
5.79
5.37
4.10
4.40

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
4,061
3,862
3,256
3,125
3,077
1,460
1,237
1,111
1,225
1,554
Fixed Assets
1,795
1,637
1,497
1,386
1,256
858
670
584
573
620
Current Assets
1,278
1,251
675
679
768
569
550
398
501
791
Capital Work in Progress
282
280
288
272
278
26
7
10
47
31
Investments
0
0
1
1
1
0
15
46
44
46
Other Assets
1,985
1,945
1,470
1,467
1,542
576
544
472
561
857
Total Liabilities
4,061
3,862
3,256
3,125
3,077
1,460
1,237
1,111
1,225
1,554
Current Liabilities
1,123
1,338
1,510
2,013
2,346
175
142
241
372
260
Non Current Liabilities
2,609
2,475
2,212
1,905
1,436
519
442
222
165
124
Total Equity
329
49
-467
-792
-704
766
653
647
689
1,170
Reserve & Surplus
244
-40
-556
-881
-793
725
544
538
579
1,050
Share Capital
85
89
89
89
89
41
41
41
41
51

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
367
-76
-240
15
57
-2
-74
-11
18
-19
Investing Activities
1,334
-2
-176
-28
46
167
67
113
-31
-312
Operating Activities
-369
212
401
9
12
81
24
93
18
126
Financing Activities
-597
-286
-465
33
-0
-250
-165
-217
31
167

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
98.07 %
90.00 %
90.00 %
90.00 %
90.00 %
89.96 %
89.96 %
89.96 %
89.96 %
72.40 %
72.40 %
69.84 %
69.84 %
69.84 %
69.84 %
69.84 %
69.84 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
4.14 %
1.96 %
1.42 %
1.94 %
2.53 %
2.69 %
DIIs
1.00 %
3.44 %
3.35 %
3.35 %
2.97 %
2.97 %
2.98 %
3.94 %
2.62 %
13.49 %
9.88 %
14.50 %
17.73 %
18.93 %
18.29 %
18.99 %
20.10 %
Government
0.00 %
0.00 %
0.04 %
0.04 %
0.04 %
0.04 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.58 %
2.34 %
2.72 %
2.83 %
3.34 %
3.69 %
3.61 %
3.44 %
3.38 %
3.10 %
3.85 %
7.79 %
7.44 %
7.16 %
7.59 %
6.42 %
5.11 %
Others
0.35 %
4.22 %
3.89 %
3.79 %
3.65 %
3.34 %
3.44 %
2.66 %
4.03 %
11.02 %
13.87 %
3.74 %
3.03 %
2.65 %
2.35 %
2.22 %
2.27 %
No of Share Holders
30,343
33,379
34,798
33,535
33,698
33,679
32,717
30,894
29,523
29,039
29,197
36,931
36,720
34,695
36,363
34,158
34,303

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %

No dividends have been distributed by the company in the past 10 years

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
26 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
26 May 2025 759.20 754.40
12 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
12 Feb 2025 1,457.50 1,245.55
11 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
11 Nov 2024 1,394.75 1,499.45
21 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
21 Aug 2024 1,147.85 1,398.00
26 Oct 2015 CHANGE OF NAME Change Of Name
NA
26 Oct 2015 0.00 0.00

Announcements

Intimation On Receipt Of EIR After The USFDA Inspection At The Plant Of The Company Situated At Alathur2 days ago
Board Comments On Fine Levied By The Exchange3 days ago
Compliances-Reg.24(A)-Annual Secretarial Compliance3 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome5 days ago
Announcement under Regulation 30 (LODR)-Newspaper Publication5 days ago
Announcement under Regulation 30 (LODR)-Investor Presentation5 days ago
Annual Audited Financial Results For The Quarter And F.Y. Ended On March 31 20255 days ago
Board Meeting Outcome for Outcome Of Board Meeting For Considering And Approving Annual Audited Financial Results For The Quarter And F.Y. Ended On March 31 20255 days ago
Notice Of Meeting Of Equity Shareholders And Unsecured Creditors Of Orchid Pharma Ltd Convened Pursuant To The Order Passed By Honble National Company Law Tribunal6 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 20, 2025
Board Meeting Intimation for The Board Meeting Scheduled To Be Held On May 26 2025May 20, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportMay 15, 2025
Intimation Related To The Scheme Of Amalgamation Of Dhanuka Laboratories Limited (Amalgamating Company) With Orchid Pharma Limited (Company/ Amalgamated Company) And Their Respective Shareholders And Creditors (The Scheme) Under Regulation 30 Of SEBI (LisMay 13, 2025
Intimation Under Regulation 30 Read With Schedule III Of SEBI Listing RegulationsMay 10, 2025
Intimation On Scheme Of Amalgamation Of Dhanuka Laboratories Limited ("Amalgamating Company") With Orchid Pharma Limited ("Company"/ "Amalgamated Company") And Their Respective Shareholders And Creditors.May 03, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 11, 2025
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /AgreementsApr 09, 2025
Intimation Of Letter(S)/Emails Received From Stock Exchanges As Cautionary Under SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 29, 2025
Closure of Trading WindowMar 27, 2025
Intimation Under Regulation 30- Scheme Of Amalgamation Of Dhanuka Laboratories Limited (Amalgamating Company) With Orchid Pharma Limited (Company/ Amalgamated Company) And Their Respective Shareholders And CreditorsMar 10, 2025
Announcement under Regulation 30 (LODR)-Credit RatingMar 07, 2025
Disclosure Regarding The Order Passed By Goods And Service Tax DepartmentFeb 28, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 19, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 15, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 12, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 12, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportFeb 12, 2025
Statement Of Deviation Or Variation For The Quarter-III Of F.Y.2024-25 Ended On December 31 2024.Feb 12, 2025
Integrated Filing (Financial)Feb 12, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 12, 2025
Outcome Of The Board Meeting Held For Inter Alia Consideration And Approval Of Unaudited Limited Reviewed Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended On DecembFeb 12, 2025
Board Meeting Outcome for Outcome Of Board MeetingFeb 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 06, 2025
Board Meeting Intimation for Intimation Of Board Meeting Scheduled To Be Held On February 12 2025Feb 06, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 13, 2025
Closure of Trading WindowDec 30, 2024
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 15, 2024
Newspaper Publication Of Unaudited Limited ReviewedFinancial Results (Standalone & Consolidated) For Quarter- II And Half Year Ended On September 30, 2024 Of Financial Year 2024-25Nov 12, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 11, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 11, 2024
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportNov 11, 2024
Statement Of Deviation Or Variation For The Quarter Ended On September 30, 2024Nov 11, 2024
Announcement under Regulation 30 (LODR)-Investor PresentationNov 11, 2024
Unaudited Financial Results For The Quarter And Half Year Ended On September 30, 2024Nov 11, 2024
Board Meeting Outcome for Outcome Of Board Meeting Held On November 11, 2024Nov 11, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 06, 2024
Board Meeting Intimation for Approval Of Unaudited Limited Reviewed Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended On September 30, 2024Nov 05, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 14, 2024
Intimation Related To The Scheme Of Amalgamation Of DhanukaLaboratories Limited ('Amalgamating Company') With Orchid Pharma Limited ('Amalgamated Company') And Their Respective Shareholders And Creditors ('The Scheme') Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 '(SEBI Listing Regulations)', As Amended.Sep 27, 2024
Intimation Of Email Received From BSE For Warning Letter Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015Sep 27, 2024

Technical Indicators

Mutual Fund Holdings

Funding HouseNo of SharesCurrent Holding %1M Change %3M Change %Month
JM Focused Direct Plan-Growth
0
0.00%
-1.12%
-1.58%
Apr 2025
JM ELSS Tax Saver Fund Direct Plan-Growth
0
0.00%
-0.68%
-0.92%
Apr 2025
Kotak Special Opportunities Fund Direct-Growth
397636
1.59%
0.59%
0.31%
Apr 2025
JM Aggressive Hybrid Fund Direct-Growth
0
0.00%
-0.55%
-0.71%
Apr 2025
Tata India Pharma & Healthcare Fund Direct-Growth
115000
0.75%
-0.33%
-0.77%
Apr 2025
UTI Healthcare Fund Direct-Growth
74285
0.57%
0.16%
0.00%
Apr 2025
Bajaj Finserv Healthcare Fund Direct-Growth
70644
1.82%
0.14%
-0.44%
Apr 2025
Tata Multi Asset Opportunities Fund Direct - Growth
0
0.00%
-0.11%
-0.40%
Apr 2025
JM Value Fund Direct Plan-Growth
82404
0.64%
0.07%
-0.11%
Apr 2025
Kotak Healthcare Fund Direct - Growth
100000
1.93%
0.04%
-0.60%
Apr 2025
JM Small Cap Fund Direct - Growth
45472
0.58%
0.04%
-0.16%
Apr 2025
JM Flexicap Fund Direct Plan-Growth
395894
0.56%
-0.04%
-0.05%
Apr 2025
Quant Small Cap Fund Direct Plan-Growth
3465947
1.06%
-0.02%
-0.40%
Apr 2025
Invesco India ESG Integration Strategy Fund Direct - Growth
34058
0.59%
0.01%
-0.16%
Apr 2025
ITI Pharma and Healthcare Fund Direct - Growth
36258
1.33%
0.01%
-0.41%
Apr 2025
ITI Value Fund Direct - Growth
32477
0.86%
0.01%
-0.27%
Apr 2025
Kotak Multi Asset Allocation Fund Direct - Growth
681494
0.70%
0.01%
-0.17%
Apr 2025
Invesco India Multicap Fund Direct-Growth
256487
0.54%
-0.01%
-0.19%
Apr 2025
Nippon India Pharma Fund Direct-Growth
492727
0.48%
0.01%
-0.14%
Apr 2025
Tata India Innovation Fund Direct-Growth
144093
0.70%
0.01%
-0.19%
Apr 2025
UTI Small Cap Fund Direct - Growth
283362
0.54%
0.01%
-0.18%
Apr 2025
Bajaj Finserv Flexi Cap Fund Direct-Growth
190399
0.34%
-0.01%
-0.14%
Apr 2025
JM Large Cap Fund Direct Plan-Growth
0
0.00%
0.00%
0.00%
Apr 2025
JM Midcap Fund Direct - Growth
0
0.00%
0.00%
-0.78%
Apr 2025
Kotak Consumption Fund Direct - Growth
266000
1.76%
0.00%
-0.45%
Apr 2025